A strong start for Madrigal’s MASH drug launch

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I fractured my elbow over the weekend. I’ll spare you all the details except to say scampering across slippery rocks is not a great idea. Perhaps my biggest mistake was believing that I’m nimble enough to scamper over anything.

advertisement

The break isn’t too serious, but my right arm is in a sling for at least a few weeks, and let me tell you, trying to write this newsletter one-handed, even using talk to text, was not easy.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe